Patient Leaflet Updated 22-Aug-2024 | AbbVie Ltd
Skyrizi 600 mg concentrate for solution for infusion
Skyrizi 600 mg concentrate for solution for infusion
risankizumab
1. What Skyrizi is and what it is used for
2. What you need to know before you are given Skyrizi
3. How Skyrizi will be given
4. Possible side effects
5. How to store Skyrizi
6. Contents of the pack and other information
Skyrizi contains the active substance risankizumab.
Skyrizi is used to treat patients 16 years and older with moderate to severe Crohn’s disease and adult patients with moderate to severe ulcerative colitis.
This medicine works by stopping a protein in the body called ‘IL-23’, which causes inflammation.
Crohn’s disease
Crohn’s disease is an inflammatory disease of the digestive tract. If you have active Crohn’s disease you will first be given other medicines. If these medicines do not work well enough, you will be given Skyrizi to treat your Crohn’s disease.
Ulcerative colitis
Ulcerative colitis is an inflammatory disease of the large bowel. If you have active ulcerative colitis you will first be given other medicines. If these medicines do not work well enough or if you cannot take these medicines, you will be given Skyrizi to treat your ulcerative colitis.
Skyrizi reduces the inflammation and can therefore help to reduce the signs and symptoms of your disease.
Talk to your doctor, pharmacist or nurse before and during the use of Skyrizi
It is important that your doctor or nurse keep a record of the batch number of your Skyrizi.
Every time you get a new pack of Skyrizi, your doctor or nurse must note down the date and the batch number (which is on the packaging after “Lot”).
Allergic reactions
Tell your doctor or seek medical help immediately if you notice any signs of an allergic reaction while you are taking Skyrizi such as
Skyrizi is not recommended for children and adolescents under 16 years of age. This is because Skyrizi has not been studied in this age group.
Tell your doctor, pharmacist or nurse:
If you are not sure, talk to your doctor, pharmacist or nurse before and during the use of Skyrizi.
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. This is because it is not known how this medicine will affect the baby.
If you are a woman who can become pregnant, you should use contraception while using this medicine and for at least 21 weeks after your last dose of Skyrizi.
If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.
Skyrizi is not likely to affect your driving and use of machines.
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free’.
You will begin treatment with Skyrizi with a starting dose which will be given by your doctor or nurse through a drip in your arm (intravenous infusion).
Starting doses
Crohn’s disease
How much?
When?
Ulcerative colitis
How much?
When?
Afterwards, you will receive Skyrizi as an injection under your skin. See package leaflet for Skyrizi 180 mg and 360 mg solution for injection in cartridge.
Maintenance doses
Crohn’s disease
How much?
When?
Ulcerative colitis
How much?
When?
If you forget or miss the appointment for any of your doses, contact your doctor to reschedule your appointment as soon as you remember.
Do not stop using Skyrizi without talking to your doctor first. If you stop treatment, your symptoms may come back.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Talk to your doctor or get medical help immediately if you have symptoms of a serious infection such as
Your doctor will decide if you can keep using Skyrizi.
Tell your doctor, pharmacist or nurse if you get any of the following side effects
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.
United Kingdom
or search for MHRA Yellow Card in the Google Play or Apple App Store.
Skyrizi 600 mg concentrate for solution for infusion is given in a hospital or clinic and patients should not need to store or handle it.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial label and outer carton after ‘EXP’.
Store in a refrigerator (2°C - 8°C). Do not freeze.
Keep the vial in the original carton in order to protect from light.
Do not shake the Skyrizi vial. Prolonged vigorous shaking can damage the medicine.
Do not use this medicine if the liquid is cloudy or contains flakes or large particles.
Do not throw away any medicines via wastewater or household waste. These measures will help protect the environment.
Skyrizi is a clear and colourless to slightly yellow liquid in a vial. The liquid may contain tiny white or clear particles.
Each pack contains 1 vial.
or
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
United Kingdom
This leaflet was last revised in 05/2024
Other sources of information
Detailed and updated information on this product is available by scanning the QR code included below or on the outer carton with a smartphone. The same information is also available at the following URL: www.skyrizi.eu
To listen to or request a copy of this leaflet in Braille, large print or audio, please contact the local representative of the Marketing Authorisation Holder.
AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK
www.abbviemedinfo.com
+44 (0)1628 561 092
+44 (0)1628 561 092
www.abbvie.co.uk